| Chi Lakewood Health | |
|
600 Main Ave S Baudette MN 56623-2855 | |
| (218) 634-1655 | |
| (218) 634-1094 |
| Full Name | Chi Lakewood Health |
|---|---|
| Speciality | Clinic/Center |
| Location | 600 Main Ave S, Baudette, Minnesota |
| Authorized Official Name and Position | Jeffry A Stampohar (PRESIDENT) |
| Authorized Official Contact | 2186342120 |
| Accepts Medicare Insurance | Yes. This clinic participates in medicare program and accept medicare insurance. |
| Mailing Address | Practice Location Address |
|---|---|
| Chi Lakewood Health 600 Main Ave S Baudette MN 56623-2855 Ph: (218) 634-1655 | Chi Lakewood Health 600 Main Ave S Baudette MN 56623-2855 Ph: (218) 634-1655 |
| NPI Number | 1972799237 |
|---|---|
| Provider Enumeration Date | 09/20/2007 |
| Last Update Date | 02/27/2020 |
| Medicare PECOS PAC ID | 5698687929 |
|---|---|
| Medicare Enrollment ID | O20031104000469 |
News Archive
Neoleukin Therapeutics, Inc., "Neoleukin" (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced the publication in Science of research describing novel molecules designed to treat or prevent infection by the virus that causes COVID-19, SARS-CoV-2.
The first comprehensive picture of female lung cancer mortality trends in Europe shows rates are still rising in most countries. But, the research does indicate that there is some room for cautious optimism in the longer term due to decreases or smaller rates of increase in some countries and a more favourable trend among younger women in many countries.
Michael Summers is the Professor of Chemistry and Biochemistry at the University of Maryland, Baltimore County, and an investigator with the Howard Hughes Medical Institute. In this interview, he tells us about his work investigating the structure of large RNAs using NMR spectroscopy.
The largest study to date of how Latina breast cancer patients evaluate treatment options highlights the need to counteract language barriers, information overload and a tendency to defer to rather than partner with doctors.
› Verified 4 days ago
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1972799237 | NPI | - | NPPES |
| 199245700 | Medicaid | MN |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 261Q00000X | Clinic/center | (* (Not Available)) | Primary |
| Provider Name | Michael J Clark |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1215967898 PECOS PAC ID: 2961307194 Enrollment ID: I20031202000073 |
News Archive
Neoleukin Therapeutics, Inc., "Neoleukin" (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced the publication in Science of research describing novel molecules designed to treat or prevent infection by the virus that causes COVID-19, SARS-CoV-2.
The first comprehensive picture of female lung cancer mortality trends in Europe shows rates are still rising in most countries. But, the research does indicate that there is some room for cautious optimism in the longer term due to decreases or smaller rates of increase in some countries and a more favourable trend among younger women in many countries.
Michael Summers is the Professor of Chemistry and Biochemistry at the University of Maryland, Baltimore County, and an investigator with the Howard Hughes Medical Institute. In this interview, he tells us about his work investigating the structure of large RNAs using NMR spectroscopy.
The largest study to date of how Latina breast cancer patients evaluate treatment options highlights the need to counteract language barriers, information overload and a tendency to defer to rather than partner with doctors.
› Verified 4 days ago
| Provider Name | Robert J Dayer |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1265471296 PECOS PAC ID: 5799680922 Enrollment ID: I20031202000081 |
News Archive
Neoleukin Therapeutics, Inc., "Neoleukin" (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced the publication in Science of research describing novel molecules designed to treat or prevent infection by the virus that causes COVID-19, SARS-CoV-2.
The first comprehensive picture of female lung cancer mortality trends in Europe shows rates are still rising in most countries. But, the research does indicate that there is some room for cautious optimism in the longer term due to decreases or smaller rates of increase in some countries and a more favourable trend among younger women in many countries.
Michael Summers is the Professor of Chemistry and Biochemistry at the University of Maryland, Baltimore County, and an investigator with the Howard Hughes Medical Institute. In this interview, he tells us about his work investigating the structure of large RNAs using NMR spectroscopy.
The largest study to date of how Latina breast cancer patients evaluate treatment options highlights the need to counteract language barriers, information overload and a tendency to defer to rather than partner with doctors.
› Verified 4 days ago
| Provider Name | Daniel Joseph Margo |
|---|---|
| Provider Type | Practitioner - General Surgery |
| Provider Identifiers | NPI Number: 1083727200 PECOS PAC ID: 2860398187 Enrollment ID: I20031209000272 |
News Archive
Neoleukin Therapeutics, Inc., "Neoleukin" (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced the publication in Science of research describing novel molecules designed to treat or prevent infection by the virus that causes COVID-19, SARS-CoV-2.
The first comprehensive picture of female lung cancer mortality trends in Europe shows rates are still rising in most countries. But, the research does indicate that there is some room for cautious optimism in the longer term due to decreases or smaller rates of increase in some countries and a more favourable trend among younger women in many countries.
Michael Summers is the Professor of Chemistry and Biochemistry at the University of Maryland, Baltimore County, and an investigator with the Howard Hughes Medical Institute. In this interview, he tells us about his work investigating the structure of large RNAs using NMR spectroscopy.
The largest study to date of how Latina breast cancer patients evaluate treatment options highlights the need to counteract language barriers, information overload and a tendency to defer to rather than partner with doctors.
› Verified 4 days ago
| Provider Name | Jerry R Bartleson |
|---|---|
| Provider Type | Practitioner - Emergency Medicine |
| Provider Identifiers | NPI Number: 1386686376 PECOS PAC ID: 0042102667 Enrollment ID: I20040625000032 |
News Archive
Neoleukin Therapeutics, Inc., "Neoleukin" (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced the publication in Science of research describing novel molecules designed to treat or prevent infection by the virus that causes COVID-19, SARS-CoV-2.
The first comprehensive picture of female lung cancer mortality trends in Europe shows rates are still rising in most countries. But, the research does indicate that there is some room for cautious optimism in the longer term due to decreases or smaller rates of increase in some countries and a more favourable trend among younger women in many countries.
Michael Summers is the Professor of Chemistry and Biochemistry at the University of Maryland, Baltimore County, and an investigator with the Howard Hughes Medical Institute. In this interview, he tells us about his work investigating the structure of large RNAs using NMR spectroscopy.
The largest study to date of how Latina breast cancer patients evaluate treatment options highlights the need to counteract language barriers, information overload and a tendency to defer to rather than partner with doctors.
› Verified 4 days ago
| Provider Name | David Javier Lopez |
|---|---|
| Provider Type | Practitioner - Psychiatry |
| Provider Identifiers | NPI Number: 1275629719 PECOS PAC ID: 0648241232 Enrollment ID: I20040805000876 |
News Archive
Neoleukin Therapeutics, Inc., "Neoleukin" (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced the publication in Science of research describing novel molecules designed to treat or prevent infection by the virus that causes COVID-19, SARS-CoV-2.
The first comprehensive picture of female lung cancer mortality trends in Europe shows rates are still rising in most countries. But, the research does indicate that there is some room for cautious optimism in the longer term due to decreases or smaller rates of increase in some countries and a more favourable trend among younger women in many countries.
Michael Summers is the Professor of Chemistry and Biochemistry at the University of Maryland, Baltimore County, and an investigator with the Howard Hughes Medical Institute. In this interview, he tells us about his work investigating the structure of large RNAs using NMR spectroscopy.
The largest study to date of how Latina breast cancer patients evaluate treatment options highlights the need to counteract language barriers, information overload and a tendency to defer to rather than partner with doctors.
› Verified 4 days ago
| Provider Name | Daniel S Vechell |
|---|---|
| Provider Type | Practitioner - Diagnostic Radiology |
| Provider Identifiers | NPI Number: 1275634628 PECOS PAC ID: 8426005414 Enrollment ID: I20050401000291 |
News Archive
Neoleukin Therapeutics, Inc., "Neoleukin" (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced the publication in Science of research describing novel molecules designed to treat or prevent infection by the virus that causes COVID-19, SARS-CoV-2.
The first comprehensive picture of female lung cancer mortality trends in Europe shows rates are still rising in most countries. But, the research does indicate that there is some room for cautious optimism in the longer term due to decreases or smaller rates of increase in some countries and a more favourable trend among younger women in many countries.
Michael Summers is the Professor of Chemistry and Biochemistry at the University of Maryland, Baltimore County, and an investigator with the Howard Hughes Medical Institute. In this interview, he tells us about his work investigating the structure of large RNAs using NMR spectroscopy.
The largest study to date of how Latina breast cancer patients evaluate treatment options highlights the need to counteract language barriers, information overload and a tendency to defer to rather than partner with doctors.
› Verified 4 days ago
| Provider Name | Fritz Leidig |
|---|---|
| Provider Type | Practitioner - Emergency Medicine |
| Provider Identifiers | NPI Number: 1871533851 PECOS PAC ID: 7113916305 Enrollment ID: I20050602000726 |
News Archive
Neoleukin Therapeutics, Inc., "Neoleukin" (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced the publication in Science of research describing novel molecules designed to treat or prevent infection by the virus that causes COVID-19, SARS-CoV-2.
The first comprehensive picture of female lung cancer mortality trends in Europe shows rates are still rising in most countries. But, the research does indicate that there is some room for cautious optimism in the longer term due to decreases or smaller rates of increase in some countries and a more favourable trend among younger women in many countries.
Michael Summers is the Professor of Chemistry and Biochemistry at the University of Maryland, Baltimore County, and an investigator with the Howard Hughes Medical Institute. In this interview, he tells us about his work investigating the structure of large RNAs using NMR spectroscopy.
The largest study to date of how Latina breast cancer patients evaluate treatment options highlights the need to counteract language barriers, information overload and a tendency to defer to rather than partner with doctors.
› Verified 4 days ago
| Provider Name | Bonita F Conner |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1497791115 PECOS PAC ID: 5799729281 Enrollment ID: I20050920000805 |
News Archive
Neoleukin Therapeutics, Inc., "Neoleukin" (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced the publication in Science of research describing novel molecules designed to treat or prevent infection by the virus that causes COVID-19, SARS-CoV-2.
The first comprehensive picture of female lung cancer mortality trends in Europe shows rates are still rising in most countries. But, the research does indicate that there is some room for cautious optimism in the longer term due to decreases or smaller rates of increase in some countries and a more favourable trend among younger women in many countries.
Michael Summers is the Professor of Chemistry and Biochemistry at the University of Maryland, Baltimore County, and an investigator with the Howard Hughes Medical Institute. In this interview, he tells us about his work investigating the structure of large RNAs using NMR spectroscopy.
The largest study to date of how Latina breast cancer patients evaluate treatment options highlights the need to counteract language barriers, information overload and a tendency to defer to rather than partner with doctors.
› Verified 4 days ago
| Provider Name | Rebecca J Poolman |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1598781353 PECOS PAC ID: 0749209609 Enrollment ID: I20051121000422 |
News Archive
Neoleukin Therapeutics, Inc., "Neoleukin" (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced the publication in Science of research describing novel molecules designed to treat or prevent infection by the virus that causes COVID-19, SARS-CoV-2.
The first comprehensive picture of female lung cancer mortality trends in Europe shows rates are still rising in most countries. But, the research does indicate that there is some room for cautious optimism in the longer term due to decreases or smaller rates of increase in some countries and a more favourable trend among younger women in many countries.
Michael Summers is the Professor of Chemistry and Biochemistry at the University of Maryland, Baltimore County, and an investigator with the Howard Hughes Medical Institute. In this interview, he tells us about his work investigating the structure of large RNAs using NMR spectroscopy.
The largest study to date of how Latina breast cancer patients evaluate treatment options highlights the need to counteract language barriers, information overload and a tendency to defer to rather than partner with doctors.
› Verified 4 days ago
| Provider Name | Janice G Carr-herseth |
|---|---|
| Provider Type | Practitioner - Clinical Social Worker |
| Provider Identifiers | NPI Number: 1881816353 PECOS PAC ID: 0749290278 Enrollment ID: I20060428000162 |
News Archive
Neoleukin Therapeutics, Inc., "Neoleukin" (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced the publication in Science of research describing novel molecules designed to treat or prevent infection by the virus that causes COVID-19, SARS-CoV-2.
The first comprehensive picture of female lung cancer mortality trends in Europe shows rates are still rising in most countries. But, the research does indicate that there is some room for cautious optimism in the longer term due to decreases or smaller rates of increase in some countries and a more favourable trend among younger women in many countries.
Michael Summers is the Professor of Chemistry and Biochemistry at the University of Maryland, Baltimore County, and an investigator with the Howard Hughes Medical Institute. In this interview, he tells us about his work investigating the structure of large RNAs using NMR spectroscopy.
The largest study to date of how Latina breast cancer patients evaluate treatment options highlights the need to counteract language barriers, information overload and a tendency to defer to rather than partner with doctors.
› Verified 4 days ago
| Provider Name | Lawrence J Lorbiecki |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1437255932 PECOS PAC ID: 0840296562 Enrollment ID: I20061019000451 |
News Archive
Neoleukin Therapeutics, Inc., "Neoleukin" (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced the publication in Science of research describing novel molecules designed to treat or prevent infection by the virus that causes COVID-19, SARS-CoV-2.
The first comprehensive picture of female lung cancer mortality trends in Europe shows rates are still rising in most countries. But, the research does indicate that there is some room for cautious optimism in the longer term due to decreases or smaller rates of increase in some countries and a more favourable trend among younger women in many countries.
Michael Summers is the Professor of Chemistry and Biochemistry at the University of Maryland, Baltimore County, and an investigator with the Howard Hughes Medical Institute. In this interview, he tells us about his work investigating the structure of large RNAs using NMR spectroscopy.
The largest study to date of how Latina breast cancer patients evaluate treatment options highlights the need to counteract language barriers, information overload and a tendency to defer to rather than partner with doctors.
› Verified 4 days ago
| Provider Name | Mohan Kumas Bangalore Puttaiah |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1619007697 PECOS PAC ID: 8123098738 Enrollment ID: I20070920000630 |
News Archive
Neoleukin Therapeutics, Inc., "Neoleukin" (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced the publication in Science of research describing novel molecules designed to treat or prevent infection by the virus that causes COVID-19, SARS-CoV-2.
The first comprehensive picture of female lung cancer mortality trends in Europe shows rates are still rising in most countries. But, the research does indicate that there is some room for cautious optimism in the longer term due to decreases or smaller rates of increase in some countries and a more favourable trend among younger women in many countries.
Michael Summers is the Professor of Chemistry and Biochemistry at the University of Maryland, Baltimore County, and an investigator with the Howard Hughes Medical Institute. In this interview, he tells us about his work investigating the structure of large RNAs using NMR spectroscopy.
The largest study to date of how Latina breast cancer patients evaluate treatment options highlights the need to counteract language barriers, information overload and a tendency to defer to rather than partner with doctors.
› Verified 4 days ago
| Provider Name | Suresh J Desilva |
|---|---|
| Provider Type | Practitioner - Emergency Medicine |
| Provider Identifiers | NPI Number: 1356304869 PECOS PAC ID: 4385619972 Enrollment ID: I20080409000542 |
News Archive
Neoleukin Therapeutics, Inc., "Neoleukin" (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced the publication in Science of research describing novel molecules designed to treat or prevent infection by the virus that causes COVID-19, SARS-CoV-2.
The first comprehensive picture of female lung cancer mortality trends in Europe shows rates are still rising in most countries. But, the research does indicate that there is some room for cautious optimism in the longer term due to decreases or smaller rates of increase in some countries and a more favourable trend among younger women in many countries.
Michael Summers is the Professor of Chemistry and Biochemistry at the University of Maryland, Baltimore County, and an investigator with the Howard Hughes Medical Institute. In this interview, he tells us about his work investigating the structure of large RNAs using NMR spectroscopy.
The largest study to date of how Latina breast cancer patients evaluate treatment options highlights the need to counteract language barriers, information overload and a tendency to defer to rather than partner with doctors.
› Verified 4 days ago
| Provider Name | Josephine M Mcintosh |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1881797462 PECOS PAC ID: 5193751519 Enrollment ID: I20080613000502 |
News Archive
Neoleukin Therapeutics, Inc., "Neoleukin" (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced the publication in Science of research describing novel molecules designed to treat or prevent infection by the virus that causes COVID-19, SARS-CoV-2.
The first comprehensive picture of female lung cancer mortality trends in Europe shows rates are still rising in most countries. But, the research does indicate that there is some room for cautious optimism in the longer term due to decreases or smaller rates of increase in some countries and a more favourable trend among younger women in many countries.
Michael Summers is the Professor of Chemistry and Biochemistry at the University of Maryland, Baltimore County, and an investigator with the Howard Hughes Medical Institute. In this interview, he tells us about his work investigating the structure of large RNAs using NMR spectroscopy.
The largest study to date of how Latina breast cancer patients evaluate treatment options highlights the need to counteract language barriers, information overload and a tendency to defer to rather than partner with doctors.
› Verified 4 days ago
| Provider Name | Erika K Beckett |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1861649071 PECOS PAC ID: 9638230279 Enrollment ID: I20081202000100 |
News Archive
Neoleukin Therapeutics, Inc., "Neoleukin" (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced the publication in Science of research describing novel molecules designed to treat or prevent infection by the virus that causes COVID-19, SARS-CoV-2.
The first comprehensive picture of female lung cancer mortality trends in Europe shows rates are still rising in most countries. But, the research does indicate that there is some room for cautious optimism in the longer term due to decreases or smaller rates of increase in some countries and a more favourable trend among younger women in many countries.
Michael Summers is the Professor of Chemistry and Biochemistry at the University of Maryland, Baltimore County, and an investigator with the Howard Hughes Medical Institute. In this interview, he tells us about his work investigating the structure of large RNAs using NMR spectroscopy.
The largest study to date of how Latina breast cancer patients evaluate treatment options highlights the need to counteract language barriers, information overload and a tendency to defer to rather than partner with doctors.
› Verified 4 days ago
| Provider Name | Omotola O Jaiyebo |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1912077421 PECOS PAC ID: 3072579630 Enrollment ID: I20090219000673 |
News Archive
Neoleukin Therapeutics, Inc., "Neoleukin" (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced the publication in Science of research describing novel molecules designed to treat or prevent infection by the virus that causes COVID-19, SARS-CoV-2.
The first comprehensive picture of female lung cancer mortality trends in Europe shows rates are still rising in most countries. But, the research does indicate that there is some room for cautious optimism in the longer term due to decreases or smaller rates of increase in some countries and a more favourable trend among younger women in many countries.
Michael Summers is the Professor of Chemistry and Biochemistry at the University of Maryland, Baltimore County, and an investigator with the Howard Hughes Medical Institute. In this interview, he tells us about his work investigating the structure of large RNAs using NMR spectroscopy.
The largest study to date of how Latina breast cancer patients evaluate treatment options highlights the need to counteract language barriers, information overload and a tendency to defer to rather than partner with doctors.
› Verified 4 days ago
| Provider Name | Michelle L Fulp |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1972782282 PECOS PAC ID: 0244300291 Enrollment ID: I20110701000229 |
News Archive
Neoleukin Therapeutics, Inc., "Neoleukin" (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced the publication in Science of research describing novel molecules designed to treat or prevent infection by the virus that causes COVID-19, SARS-CoV-2.
The first comprehensive picture of female lung cancer mortality trends in Europe shows rates are still rising in most countries. But, the research does indicate that there is some room for cautious optimism in the longer term due to decreases or smaller rates of increase in some countries and a more favourable trend among younger women in many countries.
Michael Summers is the Professor of Chemistry and Biochemistry at the University of Maryland, Baltimore County, and an investigator with the Howard Hughes Medical Institute. In this interview, he tells us about his work investigating the structure of large RNAs using NMR spectroscopy.
The largest study to date of how Latina breast cancer patients evaluate treatment options highlights the need to counteract language barriers, information overload and a tendency to defer to rather than partner with doctors.
› Verified 4 days ago
| Provider Name | Saravana Balaraman |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1972740488 PECOS PAC ID: 2365690070 Enrollment ID: I20120920000624 |
News Archive
Neoleukin Therapeutics, Inc., "Neoleukin" (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced the publication in Science of research describing novel molecules designed to treat or prevent infection by the virus that causes COVID-19, SARS-CoV-2.
The first comprehensive picture of female lung cancer mortality trends in Europe shows rates are still rising in most countries. But, the research does indicate that there is some room for cautious optimism in the longer term due to decreases or smaller rates of increase in some countries and a more favourable trend among younger women in many countries.
Michael Summers is the Professor of Chemistry and Biochemistry at the University of Maryland, Baltimore County, and an investigator with the Howard Hughes Medical Institute. In this interview, he tells us about his work investigating the structure of large RNAs using NMR spectroscopy.
The largest study to date of how Latina breast cancer patients evaluate treatment options highlights the need to counteract language barriers, information overload and a tendency to defer to rather than partner with doctors.
› Verified 4 days ago
| Provider Name | Mary Mackenburg Mohn |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1073690012 PECOS PAC ID: 3577716158 Enrollment ID: I20130109000777 |
News Archive
Neoleukin Therapeutics, Inc., "Neoleukin" (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced the publication in Science of research describing novel molecules designed to treat or prevent infection by the virus that causes COVID-19, SARS-CoV-2.
The first comprehensive picture of female lung cancer mortality trends in Europe shows rates are still rising in most countries. But, the research does indicate that there is some room for cautious optimism in the longer term due to decreases or smaller rates of increase in some countries and a more favourable trend among younger women in many countries.
Michael Summers is the Professor of Chemistry and Biochemistry at the University of Maryland, Baltimore County, and an investigator with the Howard Hughes Medical Institute. In this interview, he tells us about his work investigating the structure of large RNAs using NMR spectroscopy.
The largest study to date of how Latina breast cancer patients evaluate treatment options highlights the need to counteract language barriers, information overload and a tendency to defer to rather than partner with doctors.
› Verified 4 days ago
| Provider Name | Justin Quo |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1285947556 PECOS PAC ID: 9931342714 Enrollment ID: I20130826001067 |
News Archive
Neoleukin Therapeutics, Inc., "Neoleukin" (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced the publication in Science of research describing novel molecules designed to treat or prevent infection by the virus that causes COVID-19, SARS-CoV-2.
The first comprehensive picture of female lung cancer mortality trends in Europe shows rates are still rising in most countries. But, the research does indicate that there is some room for cautious optimism in the longer term due to decreases or smaller rates of increase in some countries and a more favourable trend among younger women in many countries.
Michael Summers is the Professor of Chemistry and Biochemistry at the University of Maryland, Baltimore County, and an investigator with the Howard Hughes Medical Institute. In this interview, he tells us about his work investigating the structure of large RNAs using NMR spectroscopy.
The largest study to date of how Latina breast cancer patients evaluate treatment options highlights the need to counteract language barriers, information overload and a tendency to defer to rather than partner with doctors.
› Verified 4 days ago
| Provider Name | Robert Anthony Wolfe |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1205905452 PECOS PAC ID: 6901891928 Enrollment ID: I20160511002588 |
News Archive
Neoleukin Therapeutics, Inc., "Neoleukin" (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced the publication in Science of research describing novel molecules designed to treat or prevent infection by the virus that causes COVID-19, SARS-CoV-2.
The first comprehensive picture of female lung cancer mortality trends in Europe shows rates are still rising in most countries. But, the research does indicate that there is some room for cautious optimism in the longer term due to decreases or smaller rates of increase in some countries and a more favourable trend among younger women in many countries.
Michael Summers is the Professor of Chemistry and Biochemistry at the University of Maryland, Baltimore County, and an investigator with the Howard Hughes Medical Institute. In this interview, he tells us about his work investigating the structure of large RNAs using NMR spectroscopy.
The largest study to date of how Latina breast cancer patients evaluate treatment options highlights the need to counteract language barriers, information overload and a tendency to defer to rather than partner with doctors.
› Verified 4 days ago
| Provider Name | Debra J Lukenbill |
|---|---|
| Provider Type | Practitioner - Certified Clinical Nurse Specialist (cns) |
| Provider Identifiers | NPI Number: 1265456370 PECOS PAC ID: 5294622569 Enrollment ID: I20161107001365 |
News Archive
Neoleukin Therapeutics, Inc., "Neoleukin" (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced the publication in Science of research describing novel molecules designed to treat or prevent infection by the virus that causes COVID-19, SARS-CoV-2.
The first comprehensive picture of female lung cancer mortality trends in Europe shows rates are still rising in most countries. But, the research does indicate that there is some room for cautious optimism in the longer term due to decreases or smaller rates of increase in some countries and a more favourable trend among younger women in many countries.
Michael Summers is the Professor of Chemistry and Biochemistry at the University of Maryland, Baltimore County, and an investigator with the Howard Hughes Medical Institute. In this interview, he tells us about his work investigating the structure of large RNAs using NMR spectroscopy.
The largest study to date of how Latina breast cancer patients evaluate treatment options highlights the need to counteract language barriers, information overload and a tendency to defer to rather than partner with doctors.
› Verified 4 days ago
| Provider Name | Michelle A Brown |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1013452333 PECOS PAC ID: 1557554870 Enrollment ID: I20170221001002 |
News Archive
Neoleukin Therapeutics, Inc., "Neoleukin" (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced the publication in Science of research describing novel molecules designed to treat or prevent infection by the virus that causes COVID-19, SARS-CoV-2.
The first comprehensive picture of female lung cancer mortality trends in Europe shows rates are still rising in most countries. But, the research does indicate that there is some room for cautious optimism in the longer term due to decreases or smaller rates of increase in some countries and a more favourable trend among younger women in many countries.
Michael Summers is the Professor of Chemistry and Biochemistry at the University of Maryland, Baltimore County, and an investigator with the Howard Hughes Medical Institute. In this interview, he tells us about his work investigating the structure of large RNAs using NMR spectroscopy.
The largest study to date of how Latina breast cancer patients evaluate treatment options highlights the need to counteract language barriers, information overload and a tendency to defer to rather than partner with doctors.
› Verified 4 days ago
| Provider Name | Anna E Stein |
|---|---|
| Provider Type | Practitioner - Clinical Psychologist |
| Provider Identifiers | NPI Number: 1790222404 PECOS PAC ID: 7315216470 Enrollment ID: I20170705000896 |
News Archive
Neoleukin Therapeutics, Inc., "Neoleukin" (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced the publication in Science of research describing novel molecules designed to treat or prevent infection by the virus that causes COVID-19, SARS-CoV-2.
The first comprehensive picture of female lung cancer mortality trends in Europe shows rates are still rising in most countries. But, the research does indicate that there is some room for cautious optimism in the longer term due to decreases or smaller rates of increase in some countries and a more favourable trend among younger women in many countries.
Michael Summers is the Professor of Chemistry and Biochemistry at the University of Maryland, Baltimore County, and an investigator with the Howard Hughes Medical Institute. In this interview, he tells us about his work investigating the structure of large RNAs using NMR spectroscopy.
The largest study to date of how Latina breast cancer patients evaluate treatment options highlights the need to counteract language barriers, information overload and a tendency to defer to rather than partner with doctors.
› Verified 4 days ago
| Provider Name | Dawn Page |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1124557103 PECOS PAC ID: 5294006581 Enrollment ID: I20170804000796 |
News Archive
Neoleukin Therapeutics, Inc., "Neoleukin" (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced the publication in Science of research describing novel molecules designed to treat or prevent infection by the virus that causes COVID-19, SARS-CoV-2.
The first comprehensive picture of female lung cancer mortality trends in Europe shows rates are still rising in most countries. But, the research does indicate that there is some room for cautious optimism in the longer term due to decreases or smaller rates of increase in some countries and a more favourable trend among younger women in many countries.
Michael Summers is the Professor of Chemistry and Biochemistry at the University of Maryland, Baltimore County, and an investigator with the Howard Hughes Medical Institute. In this interview, he tells us about his work investigating the structure of large RNAs using NMR spectroscopy.
The largest study to date of how Latina breast cancer patients evaluate treatment options highlights the need to counteract language barriers, information overload and a tendency to defer to rather than partner with doctors.
› Verified 4 days ago
| Provider Name | Jordan Reese |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1194215830 PECOS PAC ID: 5092066654 Enrollment ID: I20180920000676 |
News Archive
Neoleukin Therapeutics, Inc., "Neoleukin" (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced the publication in Science of research describing novel molecules designed to treat or prevent infection by the virus that causes COVID-19, SARS-CoV-2.
The first comprehensive picture of female lung cancer mortality trends in Europe shows rates are still rising in most countries. But, the research does indicate that there is some room for cautious optimism in the longer term due to decreases or smaller rates of increase in some countries and a more favourable trend among younger women in many countries.
Michael Summers is the Professor of Chemistry and Biochemistry at the University of Maryland, Baltimore County, and an investigator with the Howard Hughes Medical Institute. In this interview, he tells us about his work investigating the structure of large RNAs using NMR spectroscopy.
The largest study to date of how Latina breast cancer patients evaluate treatment options highlights the need to counteract language barriers, information overload and a tendency to defer to rather than partner with doctors.
› Verified 4 days ago
| Provider Name | Brian A Stanley |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1851661102 PECOS PAC ID: 8820242191 Enrollment ID: I20180928000135 |
News Archive
Neoleukin Therapeutics, Inc., "Neoleukin" (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced the publication in Science of research describing novel molecules designed to treat or prevent infection by the virus that causes COVID-19, SARS-CoV-2.
The first comprehensive picture of female lung cancer mortality trends in Europe shows rates are still rising in most countries. But, the research does indicate that there is some room for cautious optimism in the longer term due to decreases or smaller rates of increase in some countries and a more favourable trend among younger women in many countries.
Michael Summers is the Professor of Chemistry and Biochemistry at the University of Maryland, Baltimore County, and an investigator with the Howard Hughes Medical Institute. In this interview, he tells us about his work investigating the structure of large RNAs using NMR spectroscopy.
The largest study to date of how Latina breast cancer patients evaluate treatment options highlights the need to counteract language barriers, information overload and a tendency to defer to rather than partner with doctors.
› Verified 4 days ago
| Provider Name | Audrey J Brasel |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1952884041 PECOS PAC ID: 7315291879 Enrollment ID: I20181120000291 |
News Archive
Neoleukin Therapeutics, Inc., "Neoleukin" (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced the publication in Science of research describing novel molecules designed to treat or prevent infection by the virus that causes COVID-19, SARS-CoV-2.
The first comprehensive picture of female lung cancer mortality trends in Europe shows rates are still rising in most countries. But, the research does indicate that there is some room for cautious optimism in the longer term due to decreases or smaller rates of increase in some countries and a more favourable trend among younger women in many countries.
Michael Summers is the Professor of Chemistry and Biochemistry at the University of Maryland, Baltimore County, and an investigator with the Howard Hughes Medical Institute. In this interview, he tells us about his work investigating the structure of large RNAs using NMR spectroscopy.
The largest study to date of how Latina breast cancer patients evaluate treatment options highlights the need to counteract language barriers, information overload and a tendency to defer to rather than partner with doctors.
› Verified 4 days ago
| Provider Name | Dessa M Bergan |
|---|---|
| Provider Type | Practitioner - Clinical Social Worker |
| Provider Identifiers | NPI Number: 1083197024 PECOS PAC ID: 3870847148 Enrollment ID: I20181127000018 |
News Archive
Neoleukin Therapeutics, Inc., "Neoleukin" (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced the publication in Science of research describing novel molecules designed to treat or prevent infection by the virus that causes COVID-19, SARS-CoV-2.
The first comprehensive picture of female lung cancer mortality trends in Europe shows rates are still rising in most countries. But, the research does indicate that there is some room for cautious optimism in the longer term due to decreases or smaller rates of increase in some countries and a more favourable trend among younger women in many countries.
Michael Summers is the Professor of Chemistry and Biochemistry at the University of Maryland, Baltimore County, and an investigator with the Howard Hughes Medical Institute. In this interview, he tells us about his work investigating the structure of large RNAs using NMR spectroscopy.
The largest study to date of how Latina breast cancer patients evaluate treatment options highlights the need to counteract language barriers, information overload and a tendency to defer to rather than partner with doctors.
› Verified 4 days ago
| Provider Name | Josephine Moore |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1629340906 PECOS PAC ID: 9739337023 Enrollment ID: I20181127001876 |
News Archive
Neoleukin Therapeutics, Inc., "Neoleukin" (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced the publication in Science of research describing novel molecules designed to treat or prevent infection by the virus that causes COVID-19, SARS-CoV-2.
The first comprehensive picture of female lung cancer mortality trends in Europe shows rates are still rising in most countries. But, the research does indicate that there is some room for cautious optimism in the longer term due to decreases or smaller rates of increase in some countries and a more favourable trend among younger women in many countries.
Michael Summers is the Professor of Chemistry and Biochemistry at the University of Maryland, Baltimore County, and an investigator with the Howard Hughes Medical Institute. In this interview, he tells us about his work investigating the structure of large RNAs using NMR spectroscopy.
The largest study to date of how Latina breast cancer patients evaluate treatment options highlights the need to counteract language barriers, information overload and a tendency to defer to rather than partner with doctors.
› Verified 4 days ago
| Provider Name | Scott Harris |
|---|---|
| Provider Type | Practitioner - Emergency Medicine |
| Provider Identifiers | NPI Number: 1740402858 PECOS PAC ID: 5890835334 Enrollment ID: I20190805002641 |
News Archive
Neoleukin Therapeutics, Inc., "Neoleukin" (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced the publication in Science of research describing novel molecules designed to treat or prevent infection by the virus that causes COVID-19, SARS-CoV-2.
The first comprehensive picture of female lung cancer mortality trends in Europe shows rates are still rising in most countries. But, the research does indicate that there is some room for cautious optimism in the longer term due to decreases or smaller rates of increase in some countries and a more favourable trend among younger women in many countries.
Michael Summers is the Professor of Chemistry and Biochemistry at the University of Maryland, Baltimore County, and an investigator with the Howard Hughes Medical Institute. In this interview, he tells us about his work investigating the structure of large RNAs using NMR spectroscopy.
The largest study to date of how Latina breast cancer patients evaluate treatment options highlights the need to counteract language barriers, information overload and a tendency to defer to rather than partner with doctors.
› Verified 4 days ago
| Provider Name | Michelle Renee Lanning |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1144876103 PECOS PAC ID: 6709115165 Enrollment ID: I20190910001928 |
News Archive
Neoleukin Therapeutics, Inc., "Neoleukin" (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced the publication in Science of research describing novel molecules designed to treat or prevent infection by the virus that causes COVID-19, SARS-CoV-2.
The first comprehensive picture of female lung cancer mortality trends in Europe shows rates are still rising in most countries. But, the research does indicate that there is some room for cautious optimism in the longer term due to decreases or smaller rates of increase in some countries and a more favourable trend among younger women in many countries.
Michael Summers is the Professor of Chemistry and Biochemistry at the University of Maryland, Baltimore County, and an investigator with the Howard Hughes Medical Institute. In this interview, he tells us about his work investigating the structure of large RNAs using NMR spectroscopy.
The largest study to date of how Latina breast cancer patients evaluate treatment options highlights the need to counteract language barriers, information overload and a tendency to defer to rather than partner with doctors.
› Verified 4 days ago
| Provider Name | Ashley A Malchow |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1265066245 PECOS PAC ID: 8224469374 Enrollment ID: I20200506000180 |
News Archive
Neoleukin Therapeutics, Inc., "Neoleukin" (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced the publication in Science of research describing novel molecules designed to treat or prevent infection by the virus that causes COVID-19, SARS-CoV-2.
The first comprehensive picture of female lung cancer mortality trends in Europe shows rates are still rising in most countries. But, the research does indicate that there is some room for cautious optimism in the longer term due to decreases or smaller rates of increase in some countries and a more favourable trend among younger women in many countries.
Michael Summers is the Professor of Chemistry and Biochemistry at the University of Maryland, Baltimore County, and an investigator with the Howard Hughes Medical Institute. In this interview, he tells us about his work investigating the structure of large RNAs using NMR spectroscopy.
The largest study to date of how Latina breast cancer patients evaluate treatment options highlights the need to counteract language barriers, information overload and a tendency to defer to rather than partner with doctors.
› Verified 4 days ago
| Provider Name | Renee L Sandvik |
|---|---|
| Provider Type | Practitioner - Clinical Social Worker |
| Provider Identifiers | NPI Number: 1649441304 PECOS PAC ID: 7315248846 Enrollment ID: I20200814001949 |
News Archive
Neoleukin Therapeutics, Inc., "Neoleukin" (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced the publication in Science of research describing novel molecules designed to treat or prevent infection by the virus that causes COVID-19, SARS-CoV-2.
The first comprehensive picture of female lung cancer mortality trends in Europe shows rates are still rising in most countries. But, the research does indicate that there is some room for cautious optimism in the longer term due to decreases or smaller rates of increase in some countries and a more favourable trend among younger women in many countries.
Michael Summers is the Professor of Chemistry and Biochemistry at the University of Maryland, Baltimore County, and an investigator with the Howard Hughes Medical Institute. In this interview, he tells us about his work investigating the structure of large RNAs using NMR spectroscopy.
The largest study to date of how Latina breast cancer patients evaluate treatment options highlights the need to counteract language barriers, information overload and a tendency to defer to rather than partner with doctors.
› Verified 4 days ago
| Provider Name | Brady S Anderson |
|---|---|
| Provider Type | Practitioner - Clinical Social Worker |
| Provider Identifiers | NPI Number: 1881212819 PECOS PAC ID: 5294154076 Enrollment ID: I20200928002608 |
News Archive
Neoleukin Therapeutics, Inc., "Neoleukin" (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced the publication in Science of research describing novel molecules designed to treat or prevent infection by the virus that causes COVID-19, SARS-CoV-2.
The first comprehensive picture of female lung cancer mortality trends in Europe shows rates are still rising in most countries. But, the research does indicate that there is some room for cautious optimism in the longer term due to decreases or smaller rates of increase in some countries and a more favourable trend among younger women in many countries.
Michael Summers is the Professor of Chemistry and Biochemistry at the University of Maryland, Baltimore County, and an investigator with the Howard Hughes Medical Institute. In this interview, he tells us about his work investigating the structure of large RNAs using NMR spectroscopy.
The largest study to date of how Latina breast cancer patients evaluate treatment options highlights the need to counteract language barriers, information overload and a tendency to defer to rather than partner with doctors.
› Verified 4 days ago
| Provider Name | Ronald Meador |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1750570545 PECOS PAC ID: 2769426238 Enrollment ID: I20201006002204 |
News Archive
Neoleukin Therapeutics, Inc., "Neoleukin" (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced the publication in Science of research describing novel molecules designed to treat or prevent infection by the virus that causes COVID-19, SARS-CoV-2.
The first comprehensive picture of female lung cancer mortality trends in Europe shows rates are still rising in most countries. But, the research does indicate that there is some room for cautious optimism in the longer term due to decreases or smaller rates of increase in some countries and a more favourable trend among younger women in many countries.
Michael Summers is the Professor of Chemistry and Biochemistry at the University of Maryland, Baltimore County, and an investigator with the Howard Hughes Medical Institute. In this interview, he tells us about his work investigating the structure of large RNAs using NMR spectroscopy.
The largest study to date of how Latina breast cancer patients evaluate treatment options highlights the need to counteract language barriers, information overload and a tendency to defer to rather than partner with doctors.
› Verified 4 days ago
| Provider Name | Sarah J Gubbels |
|---|---|
| Provider Type | Practitioner - Clinical Social Worker |
| Provider Identifiers | NPI Number: 1043532252 PECOS PAC ID: 2062701329 Enrollment ID: I20211220002349 |
News Archive
Neoleukin Therapeutics, Inc., "Neoleukin" (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced the publication in Science of research describing novel molecules designed to treat or prevent infection by the virus that causes COVID-19, SARS-CoV-2.
The first comprehensive picture of female lung cancer mortality trends in Europe shows rates are still rising in most countries. But, the research does indicate that there is some room for cautious optimism in the longer term due to decreases or smaller rates of increase in some countries and a more favourable trend among younger women in many countries.
Michael Summers is the Professor of Chemistry and Biochemistry at the University of Maryland, Baltimore County, and an investigator with the Howard Hughes Medical Institute. In this interview, he tells us about his work investigating the structure of large RNAs using NMR spectroscopy.
The largest study to date of how Latina breast cancer patients evaluate treatment options highlights the need to counteract language barriers, information overload and a tendency to defer to rather than partner with doctors.
› Verified 4 days ago
| Provider Name | Sheila D Bullock |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1366943334 PECOS PAC ID: 8729342381 Enrollment ID: I20220422000536 |
News Archive
Neoleukin Therapeutics, Inc., "Neoleukin" (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced the publication in Science of research describing novel molecules designed to treat or prevent infection by the virus that causes COVID-19, SARS-CoV-2.
The first comprehensive picture of female lung cancer mortality trends in Europe shows rates are still rising in most countries. But, the research does indicate that there is some room for cautious optimism in the longer term due to decreases or smaller rates of increase in some countries and a more favourable trend among younger women in many countries.
Michael Summers is the Professor of Chemistry and Biochemistry at the University of Maryland, Baltimore County, and an investigator with the Howard Hughes Medical Institute. In this interview, he tells us about his work investigating the structure of large RNAs using NMR spectroscopy.
The largest study to date of how Latina breast cancer patients evaluate treatment options highlights the need to counteract language barriers, information overload and a tendency to defer to rather than partner with doctors.
› Verified 4 days ago
| Provider Name | Allison Odell |
|---|---|
| Provider Type | Practitioner - Clinical Social Worker |
| Provider Identifiers | NPI Number: 1861668972 PECOS PAC ID: 2264458942 Enrollment ID: I20230216002210 |
News Archive
Neoleukin Therapeutics, Inc., "Neoleukin" (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced the publication in Science of research describing novel molecules designed to treat or prevent infection by the virus that causes COVID-19, SARS-CoV-2.
The first comprehensive picture of female lung cancer mortality trends in Europe shows rates are still rising in most countries. But, the research does indicate that there is some room for cautious optimism in the longer term due to decreases or smaller rates of increase in some countries and a more favourable trend among younger women in many countries.
Michael Summers is the Professor of Chemistry and Biochemistry at the University of Maryland, Baltimore County, and an investigator with the Howard Hughes Medical Institute. In this interview, he tells us about his work investigating the structure of large RNAs using NMR spectroscopy.
The largest study to date of how Latina breast cancer patients evaluate treatment options highlights the need to counteract language barriers, information overload and a tendency to defer to rather than partner with doctors.
› Verified 4 days ago
| Provider Name | Sharon Falke |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1578591947 PECOS PAC ID: 8527024264 Enrollment ID: I20231024003575 |
News Archive
Neoleukin Therapeutics, Inc., "Neoleukin" (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced the publication in Science of research describing novel molecules designed to treat or prevent infection by the virus that causes COVID-19, SARS-CoV-2.
The first comprehensive picture of female lung cancer mortality trends in Europe shows rates are still rising in most countries. But, the research does indicate that there is some room for cautious optimism in the longer term due to decreases or smaller rates of increase in some countries and a more favourable trend among younger women in many countries.
Michael Summers is the Professor of Chemistry and Biochemistry at the University of Maryland, Baltimore County, and an investigator with the Howard Hughes Medical Institute. In this interview, he tells us about his work investigating the structure of large RNAs using NMR spectroscopy.
The largest study to date of how Latina breast cancer patients evaluate treatment options highlights the need to counteract language barriers, information overload and a tendency to defer to rather than partner with doctors.
› Verified 4 days ago
News Archive
Neoleukin Therapeutics, Inc., "Neoleukin" (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced the publication in Science of research describing novel molecules designed to treat or prevent infection by the virus that causes COVID-19, SARS-CoV-2.
The first comprehensive picture of female lung cancer mortality trends in Europe shows rates are still rising in most countries. But, the research does indicate that there is some room for cautious optimism in the longer term due to decreases or smaller rates of increase in some countries and a more favourable trend among younger women in many countries.
Michael Summers is the Professor of Chemistry and Biochemistry at the University of Maryland, Baltimore County, and an investigator with the Howard Hughes Medical Institute. In this interview, he tells us about his work investigating the structure of large RNAs using NMR spectroscopy.
The largest study to date of how Latina breast cancer patients evaluate treatment options highlights the need to counteract language barriers, information overload and a tendency to defer to rather than partner with doctors.
› Verified 4 days ago
Lakewood Health Center Rhc Primary Care Clinic Medicare: Medicare Enrolled Practice Location: 600 Main Ave S, Baudette, MN 56623 Phone: 218-634-1655 Fax: 218-634-1094 |